CardioDx in the News
December 10, 2010Caring.com
We've all heard the scary stories. Someone in his 40s, seemingly in perfect health, suddenly drops dead during his morning run.
December 09, 2010TIME
A heart attack starts with blockages in the blood vessels, so where better to look for predictors of heart trouble than in the blood?
September 27, 2010Wall Street Journal
This year the Innovation Awards judges chose winners in 17 categories. Here's a look at the winning entries.
May 24, 2010BioCentury
By teaming up to promote each other's tests for coronary artery disease, CardioDx Inc. and General Electric Co.'s GE Healthcare unit believe they can provide more complete answers to physicians and patients than is possible with either test alone.
March 25, 2010In Vivo
Buoyed by their success with Genomic Health, a trio of West Coast VCs have expanded their portfolios of molecular diagnostic companies, with many following similar themes. CardioDx has developed a test to distinguish between patients who should move on to cardiac imaging and those they are comfortable managing otherwise.
January 13, 2010FOX News, Atlanta, GA
Chest pain can be frightening. But doctors now have a new way of diagnosing the heart blockages that may be causing the problem.
September 07, 2009The Gray Sheet
CardioDx is gradually rolling out its Corus CAD gene expression test, which quantifies the likelihood of obstructive coronary artery disease in patients with stable chest pain and no previous history of cardiac disease
September 01, 2009HCPLive.com
CardioDX, a cardiovascular genomic diagnostics company, has completed a multi-center study validating the effectiveness of Corus CAD...
September 01, 2009Diagnostic and Invasive Cardiology
CardioDx said last week it successfully completed its multicenter validation study for Corus CAD, the first gene expression test to quantify the likelihood of obstructive coronary artery disease (CAD) in patients with stable chest pain.
August 26, 2009Clinical Lab Products
CardioDx, a cardiovascular genomic diagnostics company, announces that the company has successfully completed its multicenter validation study for Corus CAD, the first and only gene expression test to quantify the likelihood of obstructive coronary artery disease (CAD) in patients with stable chest pain.